Transcatheter Heart Valve Market Size & Outlook, 2026-2034

Transcatheter Heart Valve Market Overview

The global transcatheter heart valve market size is estimated at USD 6.63 billion in 2025 and is projected to reach USD 22.55 billion by 2034, growing at a CAGR of 14.61% during the forecast period. Remarkable growth of the market is due to the increasing prevalence of valvular heart diseases, rising awareness about minimally invasive treatment options, and strong adoption of advanced transcatheter procedures, such as TAVR.

Key Market Trends & Insights

• North America held a dominant share of the global market, accounting for 47.92% share in 2025.
• The Asia Pacific region is growing at the fastest pace, with a CAGR of 15.27%.
• Product: The transcatheter aortic valve replacement (TAVR) segment dominated the market in 2025 with a revenue share of 86.21%.
• Technology: The self-expanded transcatheter valve service segment is expected to register the fastest CAGR growth of 16.12%.
• End User: The hospitals segment dominated the market in 2025.
• The U.S. dominates the global market, valued at USD 2.50 billion in 2024 and reaching USD 2.86 billion in 2025.

Graph: U.S. Market Revenue Forecast (2022 – 2034)

Source: Straits Research

Market Size & Forecast

• 2025 Market Size: USD 6.63 billion
• 2034 Projected Market Size: USD 22.55 billion
• CAGR (2025 to 2034): 14.61%
• Dominating Region: North America
• Fastest Growing Region: Asia Pacific

The global transcatheter heart valve market encompasses advanced cardiovascular interventions aimed at replacing or repairing diseased heart valves through minimally invasive techniques, reducing the demand for open-heart surgery and improving patient recovery. By product, the market is segmented into Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral Valve Replacement (TMVR), and Transcatheter Pulmonary Valve Replacement (TPVR). TAVR dominates due to its widespread use in treating aortic stenosis among high-risk and elderly patients, while TMVR is gaining traction with innovations addressing complex mitral regurgitation cases, and TPVR is expanding in the treatment of congenital heart defects and right ventricular outflow tract dysfunction. By technology, the market is divided into balloon-expanded and self-expanded transcatheter valves; the former is preferred for controlled deployment and precision placement, whereas the latter offers flexibility in irregular or calcified anatomies. By end user, hospitals hold a major share owing to advanced cardiac facilities and experienced surgeons, while specialty clinics are witnessing increasing adoption with the rise of outpatient cardiac procedures. Continuous advancements in valve design, materials, and delivery systems, along with an aging population and expanding indications for transcatheter therapies, are driving the global market toward steady growth.

Latest Market Trends

Shift from Aortic Only Treatments to Comprehensive Valve Therapy

A major trend in the transcatheter heart valve market is evolving beyond aortic valve replacement to include treatments for mitral and tricuspid valve diseases. In April 2024, Abbott received FDA approval for its TriClip device, a transcatheter edge-to-edge repair system designed to treat tricuspid regurgitation (TR). Such approval marked an advancement in the treatment of TR, a condition involving a leaky tricuspid valve, offering patients a safer, less invasive treatment option that reduced recovery time and hospital stay.

Shift from Manual Procedures to Image-Guided and Robotic-Assisted THV Interventions

A major trend in the transcatheter heart valve (THV) market is the transition from traditional, manually guided procedures to advanced, image-guided and robotic-assisted interventions. Recently, Medtronic announced the successful completion of the first commercial transcatheter heart valve procedure using the Hugo robotic-assisted surgery system in Korea at Seoul National University Hospital. Such a trend reflected the broader global movement towards incorporating robotic-assisted technologies in surgical practices, aiming to improve patient outcomes and operational efficiencies.

To get more insights about this report Download Free Sample Report

Transcatheter Heart Valve Market Driver

Advancements in Transcatheter Heart Valve (THV) Technologies

The driver for the growth of the global market is the continuous innovation in valve design, delivery systems, and procedural techniques. For example, in August 2024, Boston Scientific announced that its ACURATE Prime Aortic Valve System received CE Mark approval. This advanced transcatheter aortic valve replacement (TAVR) system featured a self-expanding design and a refined deployment mechanism, enhancing the accuracy of valve positioning. Such advancements enhanced the market growth by improving procedural outcomes and expanding treatment options for patients with heart valve diseases.

Market Restraint

High Cost of Transcatheter Heart Valve Procedures

A restraint in the transcatheter heart valve market is the high cost associated with procedures, such as transcatheter aortic valve replacement (TAVR). As per the article published in the American Heart Association, Inc., commercial prices for cardiac valve surgery ranged from USD 27,550 to USD 176,321. Such a high cost barrier created a challenge for healthcare providers and patients, particularly in regions with limited healthcare budgets. It underscored the demand for cost-efficient solutions and potential policy interventions to make these lifesaving procedures more accessible to a larger segment of the population.

Market Opportunity

Expansion of Treatment Indications

An opportunity in the transcatheter heart valve market is the expansion of treatment indications beyond traditional patient populations, particularly for conditions such as aortic regurgitation (AR). For example, in August 2025, the U.S. Food and Drug Administration (FDA) approved the use of transcatheter aortic valve replacement (TAVR) for patients with symptomatic severe aortic regurgitation who are at high or extreme risk for open heart surgery. Such factors opened up a new patient segment for TAVR procedures, which further supported in expanding the potential market.

Regional Analysis

The North America region dominated the market with a revenue share of 47.92% in 2025. The growth is attributed to factors such as the region’s high procedural volume combined with extensive physician expertise, which further ensures better outcomes and greater adoption of transcatheter heart valve therapies.

The transcatheter heart valve market in the U.S. is widely driven by the Centers for Medicare & Medicaid Services (CMS) expanding coverage to include Transcatheter Tricuspid Valve Replacement (TTVR) for symptomatic tricuspid regurgitation from March 2025. Such a factor allows more patients to get treatment, which further boosts the demand and enhances the market growth.

Asia Pacific Market Insights

The Asia Pacific region is the fastest-growing region with a CAGR of 15.27% during the forecast timeframe. The growth is attributed to factors such as government initiatives and regulatory approvals that are facilitating easier access to advanced medical technologies.

The transcatheter heart valve market in China is fuelled by the inclusion of advanced TAVI devices, such as SAPIEN 3 by Edwards Lifesciences Corporation, which is also under provincial medical insurance catalogues. Such a policy has led to a price reduction of over 40% since 2020, which further expands the market size by making treatment more accessible across the country.

Pie Chart: Regional Market Share, 2025

Source: Straits Research

Europe Market Insights

The transcatheter heart valve market in Europe is propelling due to the National Health Service’s (NHS) strategic focus on reducing waiting times for transcatheter aortic valve implantation (TAVI) procedures. In 2022/23, NHS centres performed 7,669 TAVI procedures, marking a 13% increase from the previous year. This proactive approach enhanced patient access to life-saving treatments, thereby expanding the market size and fostering sustained market growth.

In Germany, the transcatheter heart valve market is driven by the country's early adoption of transcatheter aortic valve replacement procedures. With over 25,000 TAVR procedures performed annually, this early adoption strengthens infrastructure and expertise. Therefore, such widespread adoption has established a potent infrastructure and expertise, contributing to the market's expansion.

Product Insights

The transcatheter aortic valve replacement (TAVR) segment dominated the market in 2025 with a revenue share of 86.21%. The growth is attributed to the increasing prevalence of aortic stenosis, rising awareness about early diagnosis, and the growing preference for minimally invasive cardiac procedures.

The transcatheter mitral valve replacement (TMVR) segment is anticipated to register the fastest CAGR of 15.52% during the forecast period, due to the rising prevalence of mitral regurgitation, a complex and under-treated condition, and the ongoing development of advanced TMVR devices that address anatomical and procedural challenges associated with the mitral valve’s structure.

Source: Straits Research

Technology Insights

The self-expanded transcatheter valve segment is anticipated to grow at a CAGR of 16.12% from 2026-2034. This growth is attributed to the valve’s minimally invasive design, which allows for easier implantation in patients with complex or calcified aortic anatomies. Additionally, self-expanded valves offer better hemodynamic performance, reduced risk of paravalvular leakage, and shorter procedure times compared to other valve types.

The balloon expanded transcatheter valve dominated the market in 2025, due to its high procedural precision, controlled deployment, and superior positioning accuracy, which ensure optimal valve placement and reduced risk of paravalvular leakage.

End User Insights

The hospitals segment dominated the market in 2025. The growth is attributed to the availability of advanced surgical facilities, a higher volume of cardiovascular procedures performed in hospital settings, and the presence of skilled cardiologists and cardiac care specialists.

The specialty clinics is anticipated to register the fastest CAGR of 15.23% during the forecast period, owing to the growing preference for minimally invasive cardiac procedures in outpatient settings, rising establishment of dedicated heart centers, and increasing accessibility to advanced transcatheter technologies outside large hospital systems.

Competitive Landscape

The global transcatheter heart valve market is moderately fragmented, with a few players holding shares, while several emerging participants are strengthening their presence through advanced product launches, clinical trials, and regional expansions.

MicroPort Scientific Corporation: An emerging market player

MicroPort Scientific Corporation is an emerging player in the transcatheter heart valve market, specializing in advanced transcatheter aortic valve implantation (TAVI) systems.

• In May 2024, MicroPort Scientific Corporation obtained its CE certification for the second-generation transcatheter aortic valve implantation product, VitaFlow Liverty Transcatheter Aortic Valve and Retrievable Delivery System.

List of key players in Transcatheter Heart Valve Market

1. Meril Life Sciences
2. 4C Medical Technologies, Inc.
3. Boston Scientific Corporation 
4. Braile Biomédica
5. Direct Flow Medical, Inc.
6. Edwards Lifesciences Corporation
7. JenaValve 
8. Abbott
9. Medtronic
10. HighLife Medical
11. Venus Medtech (Hangzhou) Inc. 
12. Peijia Medical Limited.
13. Micro Interventional Devices
14. Colibri Heart Valve
15. Foldax
16. INNOVHEART SRL
17. LivaNova PLC
18. TCTMD
19. Xeltis
20. Artivion, Inc
21. Others

To get more findings about this report Download Market Share

Strategic Initiatives

• November 2024: Meril Life Sciences launched the Myval Octapro Transcatheter Heart Valve at major cardiology conferences.
• May 2024: 4C Medical Technologies, Inc. announced FDA approval for its transcatheter mitral valve replacement device, “AltaValve System”.
• September 2024: Venus Medtech achieved a major milestone by performing the first two procedures of its newly designed balloon expandable valve system, Venus Vitae, during the international clinical trial Venus Vitae SMART ALIGN at Prince of Wales Hospital in Hong Kong, China.